PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

CluePoints Launches Risk-Based Monitoring Starter Pack to Drive Regulatory Compliance

The research undertaken by CluePoints highlighted the fact that many SMEs are unsure of how to embrace RBM and often how it might add significant value. The starter pack addresses this problem through the use of consultation on the ICH E6 addendum and RBM methodology. The aim is to help organizations fundamentally understand what the regulation wants, and demonstrate how a risk-based approach meets the compliance obligations and, at the same time, improves both cost and resource efficiencies.
The consultation also details the key software elements included in the starter pack. The software provides the necessary tools for organizations to start implementing a risk-based approach without overcomplicating the process, and gives users the freedom and opportunity to implement further RBM activities as and when required. Included in the starter pack are a Risk Assessment (RACT) Starter Kit, Key Risk Indicator Starter Kit, Patient Profiles Starter Kit, access to CluePoints proprietary Signals and Actions Tracking Management System and CluePoints Central Monitoring Platform Training.
“Since the introduction of the ICH E6 (R2) addendum, the industry has seen an increase in the implementation of a variety of RBM methodologies and technologies. However, we found through extensive research that SMEs are more reluctant to adopt as they perceive these types of approaches to be expensive and complicated. Consequently, they are generally unsure of the steps they need to take to implement an RBM strategy” comments Patrick Hughes, Chief Commercial Officer, CluePoints. “As we see the industry change and evolve, the starter pack is a fit-for-purpose, affordable way for SMEs to learn how the regulations will impact them, and to understand how an RBM approach can be implemented quickly and efficiently to suit their specific needs. This gives them a solution for ICH E6 compliance that will support them from pre-study risk assessment through to database lock and submission.”
For further information on the “CluePoints RBM and ICH E6 (R2) Starter Pack”, please visit http://cluepoints.com/risk-based-monitoring-starter-pack/

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026